Aditxt Inc. announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test, a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first enrollment site, Dedicated to Women OB/GYN in Dover, Delaware, has begun recruiting participants for the clinical validation study. Pearsanta President Chris Mitton stated that this milestone supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis, potentially transforming how the condition is diagnosed and managed.
Endometriosis currently requires laparoscopic surgery for definitive diagnosis, an invasive procedure that can delay treatment and diagnosis for many patients. The blood-based MET test represents a significant advancement in women's health diagnostics, offering the potential for earlier intervention and improved patient outcomes. The clinical study represents a critical step toward validating this innovative approach to endometriosis detection. The initiation of this large-scale clinical study marks an important development in women's healthcare, addressing a significant unmet need in endometriosis diagnosis. If successfully validated, the blood-based test could provide millions of women worldwide with a less invasive, more accessible diagnostic option for a condition that often takes years to properly diagnose using current methods.
Aditxt operates as a social innovation platform advancing health innovations across multiple programs, including women's health, autoimmunity, cancer and early disease detection, and infectious diseases. The company's latest news and updates are available in its newsroom at https://ibn.fm/ADTX. The full press release detailing the clinical study initiation can be viewed at https://ibn.fm/WiIhM.
